Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    TH-302
Show Display Options
RSS Create an RSS feed from your search for:
TH-302
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
2 Active, not recruiting A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Conditions: Neuroendocrine Tumors;   Pancreatic Neoplasms
Intervention: Drug: TH-302 + Sunitinib
3 Active, not recruiting A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: TH-302
4 Completed Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Conditions: Non-Small Cell Lung Cancer;   Prostate Cancer;   Pancreatic Cancer
Intervention: Drug: TH-302
5 Completed Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: TH-302
6 Completed A Phase 1 TH-302 Mass Balance Trial
Condition: Solid Tumor
Interventions: Drug: [14C] TH-302 (Label 1);   Drug: [14C] TH-302 (Label 2);   Drug: Unlabeled TH-302
7 Completed A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin;   Drug: Doxorubicin
8 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
9 Active, not recruiting A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: TH-302
10 Terminated Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: TH-302 combination with pemetrexed;   Drug: Matched placebo in combination with pemetrexed
11 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Conditions: Tumors;   Hypoxia
Intervention: Drug: TH-302
12 Terminated A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302;   Drug: Doxorubicin
13 Completed Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
Condition: HIGH GRADE GLIOMA
Interventions: Drug: TH-302;   Drug: Placebo
14 Recruiting TH-302 in Combination With Bevacizumab for Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: TH-302
15 Suspended Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate
16 Active, not recruiting Dose Escalation Study of Pazopanib Plus TH-302
Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
17 Completed A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Conditions: Solid Tumor;   Pancreatic Cancer
Interventions: Drug: TH-302 monotherapy;   Drug: TH-302;   Drug: Gemcitabine
18 Recruiting Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Intervention: Drug: TH-302 monotherapy
19 Terminated Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: TH-302;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
20 Completed Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine);   Drug: TH-302

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.